Drug intelligence / Profile preview

ANT-01

Development stage: Unknown
Lead developer: ANeuroTech
Modality: Small Molecules
Administration: Oral

Overview

ANT-01 is an investigational adjunctive anti-depression drug developed by ANeuroTech for Major Depressive Disorder (MDD). It is a low-dose (15mg) oral formulation of pipamperone dihydrochloride, an existing typical antipsychotic. ANT-01 acts as a highly selective serotonin 5-HT2A and dopamine D4 receptor antagonist. It aims to improve emotional blunting and cognitive function in MDD patients who have an insufficient response to first-line antidepressants (SSRIs/SNRI), with a favorable safety profile.

Other names: low dose pipamperone dihydrochloride

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on ANT-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-01.

Explore the full profile